CSBio CSBio

X
[{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Forma Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GEMoaB Announces First Patient Apheresed in a Phase IA Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"GEMoaB"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Highlight Clinical Data on Vitrakvi\u00ae (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming AACR Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"GEMoaB"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene Enters Phase I Clinical Development with its TCR-T Immunotherapy MDG1021 in Hematological Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Medigene"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Mundipharma's Tinostamustine in EU for Very Rare form of Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Mundipharma"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Advances Novel Bi-specific TRAILR2\/CDH17 Antibody to Phase 1 Clinical Trial for Gastrointestinal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Doses First Patient in Phase 1 Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Affimed"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data Being Presented at SITC Underscore Promising Combinations of Affimed\u2019s AFM13 and Cytokine-Activated NK Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Affimed"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Phase I Data from ACTolog\u00ae Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"Affimed","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Publishes Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD\u2019s KEYTRUDA\u00ae in Blood","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Affimed"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiation of First UniCAR Cellular Immunotherapy Study in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"GEMoaB"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CureVac"},{"orgOrder":0,"company":"Merck Group","sponsor":"Genome & Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genome and Company Ink 2nd Clinical Trial Collaboration and Supply Agreement with Merck KGA and Pfizer for Immuno-Oncology Microbiome Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Merck Group"},{"orgOrder":0,"company":"Merck Group","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Announces Collaboration with Merck KGaA and Pfizer to Evaluate XL092 and Avelumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Merck Group"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine\u00ae Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"GEMoaB"},{"orgOrder":0,"company":"Qiagen","sponsor":"OncXerna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QIAGEN and OncXerna Therapeutics Sign Diagnostic Agreements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Qiagen"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRP\u03b1 Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm To Present Update From GDF-15 Targeting First-in-Human I\/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CatalYm"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 Targeting First-in-Human Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CatalYm"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vincerx Pharma Announces $50 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Vincerx Pharma"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CureVac"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Vincerx Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRP\u00ce\u00b1 Inhibitor BI 765063 in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vincerx Pharma"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb\/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vincerx Pharma"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Immatics"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo\u00ae (nivolumab) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb\/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vincerx Pharma"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Provides Key Strategic Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vincerx Pharma"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Isotope Technologies Munich"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine\u00ae TCR-T Candidate IMA203CD8 Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces $110 Million Underwritten Offering of Ordinary Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data Update on ACTengine\u00ae IMA203 TCR-T Monotherapy Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"AvenCell Therapeutics"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"CureVac"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProBioGen\u2019s Vaccine Production Cell Line AGE1.CR.pIX\u00ae Used for Clinical Production","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"ProBioGen"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"University Hospital Muenster","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM, Helmholtz Munich and University Hospital M\u00fcnster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Isotope Technologies Munich"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed \/ Refractory CD123-Positive Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Affimed"},{"orgOrder":0,"company":"ProBioGen","sponsor":"ImmunOs Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"ProBioGen"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine\u00ae IMA203 TCR-T Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ariceum Therapeutics Doses First Patient with Its First-in-class Targeted Radiopharmaceutical Drug Satoreotide in Its Phase Ib Study in Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Ariceum Therapeutics"},{"orgOrder":0,"company":"Immatics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$1,820.0 million","upfrontCash":"$120.0 million","newsHeadline":"Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"MorphoSys"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Vincerx Pharma"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine\u00ae IMA203 TCR-T Monotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Broad Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Broad Institute Extend Cancer Therapy Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data from ACTengine\u00ae IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces Pricing of $175 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"}]

Find Oncology Drugs in Phase I Clinical Development in GERMANY

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The proceeds will be used to fund the continued research and development of company's pipeline, including IMA-203, an adoptive T-cell therapy targeting PRAME (preferentially expressed antigen in melanoma).

            Lead Product(s): IMA203,Nivolumab

            Therapeutic Area: Oncology Product Name: IMA203

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Jefferies

            Deal Size: $175.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering January 17, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma, a protein frequently expressed in a large variety of solid cancers, it has potential to address a broad cancer patient population.

            Lead Product(s): IMA203,Nivolumab

            Therapeutic Area: Oncology Product Name: IMA203

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 08, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The research collaboration is aimed at identifying cancer targets and exploring novel therapeutic approaches in oncology with the goal of bringing more medicines to patients and has already yielded three clinical oncology candidates.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Broad Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma, a protein frequently expressed in a large variety of solid cancers, it has potential to address a broad cancer patient population.

            Lead Product(s): IMA203,Nivolumab

            Therapeutic Area: Oncology Product Name: IMA203

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            VIP943 is a novel ADC developed using Vincerx’s next-generation ADC technology designed to bind with CD123 and is being investigated in acute myeloid leukemia.

            Lead Product(s): VIP943

            Therapeutic Area: Oncology Product Name: VIP943

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CPI-0209 (tulmimetostat) is an investigational compound designed to exert anti-tumor activity by inhibiting the EZH2 and EZH1, which is investigated for the treatment of endometrial cancer.

            Lead Product(s): Tulmimetostat,Carboplatin

            Therapeutic Area: Oncology Product Name: CPI-0209

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The companies will leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s mRNA technology to develop novel oncology therapies and evaluate Immatics’ investigational IMA203 PRAME TCR-T in combination with Moderna’s investigational PRAME mRNA cancer vaccine.

            Lead Product(s): IMA203,PRAME mRNA Vaccine

            Therapeutic Area: Oncology Product Name: IMA203

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: $1,820.0 million Upfront Cash: $120.0 million

            Deal Type: Collaboration September 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            177Lu-OPS201 (satoreotide) is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer.

            Lead Product(s): 68Ga-satoreotide Trizoxetan,177Lu-satoreotide Tetraxetan

            Therapeutic Area: Oncology Product Name: SSO120

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds will fund the development of Immatics' differentiated platform technologies that are the foundation of its TCR-based cell therapies including, IMA203 and bispecifics.

            Lead Product(s): TCR-T Cell Therapy,Nivolumab

            Therapeutic Area: Oncology Product Name: IMA203

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bristol Myers Squibb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing July 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CVGBM is CureVac's first investigational cancer vaccine based on its proprietary second-generation mRNA backbone designed for improved mRNA translation and increased as well as extended protein expression, which is investigated for the treatment of Glioblastoma.

            Lead Product(s): CVGBM

            Therapeutic Area: Oncology Product Name: CVGBM

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY